Earnings call transcript: Zions Bancorporation beats Q1 2026 EPS forecasts

Zions Bancorporation reported Q1 2026 EPS of $1.56, beating the $1.42 consensus by 9.86%, while revenue of $849 million missed by 0.77%; the stock fell 1.02% in aftermarket trading to $62.09. Net interest margin improved 17 bps year over year to 3.27%, deposits rose 1.8% from year-end, and management guided to Q2 2026 EPS of $1.54 and full-year 2026 EPS of $6.17. The bank also highlighted growth initiatives including new consumer and small business deposit products, capital markets expansion, and an acquisition of Basis Investment Group’s agency lending business.

Analysis

Zions is transitioning from a rate-beta story to a franchise-quality story: the key change is not the modest beat, but the improving composition of revenue. Deposit remixing away from higher-cost wholesale funding, plus the deliberate migration of off-balance-sheet balances back on balance sheet, can keep funding costs falling even if the rate backdrop stops helping. That creates a more durable NII runway than consensus is likely modeling, because the upside comes from mix and balance-sheet optimization rather than just spread carry.

The market is probably underestimating the second-order value of the bank’s product and platform investments. The new consumer/small-business deposit products and the expanded capital markets/agency lending footprint should improve deposit stickiness and cross-sell, but the bigger implication is that Zions is building a lower-beta funding base tied to operating relationships, not rate-sensitive rate shoppers. That matters because it reduces deposit competition intensity over time and gives them optionality to reinvest securities runoff into higher-ROA assets without sacrificing liquidity.

The main risk is that investors read the quarter as peak-good and fade it because the headline growth still looks modest. That would be premature if the pipeline converts and if CRE stabilization continues without credit noise; the more relevant near-term catalyst is 2Q guidance, where management has already positioned for upside on NII and fees. The real invalidation point is not revenue miss fatigue, but a sudden halt in deposit remixing or a material slowdown in C&I/CRE pricing discipline over the next 1-2 quarters.

Contrarianly, the market may be too focused on what Zions is not doing—aggressive loan growth or massive buybacks—rather than what it is building: a cleaner funding mix, more fee adjacency, and optional capital return once AOCI and regulatory visibility improve. If the Basel capital discussion lands favorably, this becomes a double lever: higher distributable capital plus better earnings quality. That combination can rerate a regional bank even without explosive balance-sheet growth.

Key Decisions for Investors

• Long ZION vs. KRE for 1-3 months: ZION has a clearer path to margin support and capital return optionality; risk is a broad regional bank de-risking tape if rates reprice lower faster than expected.
• Buy ZION common into any post-earnings weakness below the current range; target is a 8-12% move over 2-3 months if 2Q guide confirms NII/fee upside. Stop if deposit remixing stalls or CRE commentary turns defensive.
• Overlay: sell 1-2 month downside puts on ZION to harvest elevated event vol while management’s guidance bias remains constructive; best suited if shares fail to re-rate immediately on the print.
• Pair trade: long ZION / short a more deposit-beta-sensitive regional with less funding diversification over the next quarter. Thesis is relative NIM resilience and better capital flexibility, with catalyst risk centered on upcoming deposit and NII data.
• If shares rally on 2Q guide, trim into strength rather than chase; the next leg higher likely needs either a formal capital return step-up or visible traction from the new product launches.